Multimodality Management of Sarcomas (2nd Edition)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 May 2026 | Viewed by 2120
Special Issue Editor
Interests: sarcoma; melanoma; breast cancer; colorectal cancer; peritoneal carcinomatosis; intraperitoneal chemotherapy; HIPEC
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is the second edition of "Multimodality Management of Sarcomas".
Due to their rarity and heterogeneity, with a wide variety of histological subtypes, biological behaviors, and tumor localization, the optimal management of sarcomas remains challenging. The treatment of sarcomas has to be individualized and typically consists of a combination of modalities. Currently, sarcomas are managed in a multimodal manner.
Initial appropriate imaging is of the utmost importance to demonstrate the exact localization and extension of the tumor, as well as its relation to adjacent structures, in order to facilitate the performance of a diagnostic core needle biopsy and the planning of a surgical procedure when systemic disease is excluded. A preoperative biopsy is of the utmost importance to differentiate between benign and malignant tumors and to define the sarcoma subtype. The pathological examination of those rare and heterogeneous sarcoma tumors is very demanding and a significant level of expertise is required. The treatment plan for each sarcoma is personalized according to its imaging and pathology.
Until recently, most extremity soft tissue sarcomas were locally treated with amputation; currently, the majority of patients receive a limb-salvage treatment with a wide excision of the tumor, along with radiotherapy. Current evidence shows that preoperative radiotherapy may be preferred over the typical postoperative radiotherapy, whereas in low-risk patients, radiotherapy may even be omitted. In selected cases, preoperative systemic chemotherapy or isolated limb perfusion may be indicated in an attempt to preserve the extremity. For retroperitoneal sarcomas, recently, a more aggressive surgical approach has been advocated for, whereas the exact role of preoperative radiotherapy or chemotherapy to facilitate resection and to reduce the high risk of local recurrence has still to be defined. The systemic therapy of soft tissue sarcomas, either as an adjuvant treatment or for metastatic disease, has evolved from the classical anthracycline-based regimen to a more individualized histology-driven chemotherapy, whereas novel drugs have been developed. Bone sarcomas are also usually managed in a multimodal manner, depending on the histological type. Although localized chondrosarcomas are initially treated by surgical excision and/or radiotherapy, Ewing sarcomas are traditionally treated with systemic chemotherapy, followed by local treatment, including surgery and/or radiotherapy, as well as the continuation of systemic chemotherapy. Similarly, osteosarcomas are usually treated with a combination of chemotherapy and surgery, with or without radiotherapy, and the continuation of chemotherapy.
As has been illustrated, the management of sarcomas is challenging and multimodal, including radiology and pathology for initial diagnosis and, subsequently, surgery, as well as the use of chemotherapy and/or radiotherapy for definite treatment, in order to achieve optimal oncological and functional outcomes. The various aspects of this multimodal management technique and its current role will be discussed in this Special Issue.
Prof. Dr. Eelco de Bree
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- sarcomas
- multimodal
- pathology
- radiology
- surgery
- chemotherapy
- radiotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
Related Special Issue
- Multimodality Management of Sarcomas in Cancers (17 articles)
